Global Irritable Bowel Syndrome Treatment Market Growth Forecast Analysis By Manufacturers, Regions, Share And Size To 2026

Title:
Global Irritable Bowel Syndrome Treatment Market with Top Key Players data : Development
Status Along With Future Trend To 2026
Keywords:
Irritable Bowel Syndrome Treatment Market,
Irritable Bowel Syndrome Treatment Market Analysis,
Irritable Bowel Syndrome Treatment Market Outlook,
Irritable Bowel Syndrome Treatment Market Trends,
The treatment of irritable bowel syndrome majorly revolves around relieving the patient from the
symptoms associated with the condition, as the causes behind occurrence of irritable bowel
syndrome are yet to be established. Patients suffering from irritable bowel syndrome show
symptoms such as abdominal pain, diarrhea, and constipation. Long-term and recurring presence of
these symptoms signals the possibility of irritable bowel syndrome. The treatment depends on
severity of these symptoms, which are distinguished as mild, moderate, and severe. Mild symptoms
do not significantly affect the quality of life. However, severe symptoms are more frequent and
intense and need to be addressed. The disease is often linked with dietary, lifestyle factors, and
stress, which can be controlled by managing stress levels, diet, and exercise. Severe symptoms need
to be treated through medication prescribed by physicians. Two major therapy options are available
for the treatment of IBS, namely, medical or drug therapy and nutritional therapy. Medical therapy
includes drugs for relieving the symptoms and nutritional therapy by using fibers and probiotics or
prebiotics depending on the situation.
Some major players operating in the irritable bowel syndrome treatment market are Abbott
Laboratories, Synergy Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Valeant
Pharmaceuticals International, Inc., Ardelyx, Inc., Astellas Pharma Inc., Novartis AG,
GlaxoSmithKline plc., and Ironwood Pharmaceuticals, Inc.
Request Sample Copy Of This Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/506
Market Dynamics
The rise in number of gastrointestinal disorders are leading to increasing prevalence of irritable
bowel syndrome, for which various companies such as Ironwood Pharmaceuticals, Inc. as well as
NGOs conduct mass workshops for educating the people to incorporate healthy food habits as a
major precaution towards prevention of IBS. Furthermore, major growth drivers for the irritable
bowel syndrome treatment market are expected launches of various pipeline drugs for the treatment
during the forecast period and increase in levels of stress associated with changing lifestyle as
people suffering from IBS have a colon with sensitivity towards certain foods and stress. According
to a survey by Buscopan IBS Relief in 2016, stress was the cause for seven out of ten patients
suffering from gastrointestinal pain. The large population of stress and anxiety disorder patients are
expected to fuel the growth of the global irritable bowel syndrome treatment market.
Market Taxonomy
This report segments the global irritable bowel syndrome treatment market on the basis of drug
type, medical condition, and distribution channel. On the basis of drug type, the global irritable
bowel syndrome treatment market is segmented into lubiprostone, linaclotide, eluxadoline,
rifaximin, Ramosetron Hydrochloride and others. Medical conditions of irritable bowel syndrome
includes IBS-constipation and IBS-diarrhea. Irritable bowel syndrome treatment market is
segmented by distribution channel as hospital pharmacies, online pharmacies and retail pharmacies.
Key features of the study:
This report provides in-depth analysis of irritable bowel syndrome treatment market and provides
market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period
(2017–2025), considering 2017 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive
investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product
launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global irritable bowel syndrome treatment market based on the
following parameters – company overview, financial performance, product portfolio, geographical
presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Abbott Laboratories*, Synergy
Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc.,
Ardelyx, Inc., Astellas Pharma Inc., Novartis AG, GlaxoSmithKline plc., Ironwood
Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies
to make informed decision regarding their future product launch, technology up-gradation, market
expansion, and marketing tactics
The global irritable bowel syndrome treatment market report caters to various stakeholders in this
industry including investors, suppliers, drug manufacturers, distributors, new entrants, and financial
analysts
Stakeholders would have ease in decision making through the various strategy matrices used in
analyzing the Irritable Bowel Syndrome Treatment Market
Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/506
Detailed Segmentation:
Global Irritable Bowel Syndrome Treatment Market, By Drug Type:
Lubiprostone
Linaclotide
Global Irritable Bowel Syndrome Treatment Market, By Medical Condition:
IBS-Constipation
IBS-Diarrhea
Global Irritable Bowel Syndrome Treatment Market, By Distribution Channel:
Hospital Pharmacies
Global Irritable Bowel Syndrome Treatment Market, By Geography:
North America
Europe
Asia-Pacific
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]

Irritable bowel syndrome is a gastrointestinal tract disorder characterized by abdominal pain and altered bowel habits. It hampers the natural movement of intestinal muscle linings to move food along the digestive tract.